- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04942691
Prevention of Osteoporosis: Effects of Mini-trampoline Training on the Bone Remodeling (TRAMBONE)
June 25, 2021 updated by: Patrizia Proia, University of Palermo
Sport and Prevention of Bone Resorption
The aim of the project is to study the effects on bone remodeling induced by training carried out with the trampoline in order to evaluate the reduction of the resorption itself and therefore the onset of osteoporosis in women.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Bone mineral density is modified by various factors and in particular by diet, nutritional status and exercise recommended to preserve or increase bone mass in adults.
The degree of bone formation and resorption can be assessed by measuring bone resorption markers in the blood or urine.
To date, there is no information about the effect of training with an elastic trampoline on the reduction of bone resorption.
The aim of the project is to study the effects on bone remodeling induced by training carried out with the trampoline, in order to evaluate the reduction of the resorption itself and therefore the onset of osteoporosis in women.
To examine whether exercise affects bone remodeling, the C-terminal telopeptide bone resorption markers (CTX) and osteocalcin formation marker will be measured.
For the evaluation of bone metabolism osteocalcin parathyroid hormone, Calcitonin, Vitamin D, Calcium, albumin, Phosphate, Potassium markers will be evaluated.
The markers can be detected in serum.
Women with no previous experience with the trampoline activity will participate in the project randomly assigned to the experimental training group (Jumpers) or to the control group, who will not do any training during the observation period (not Jumpers).
The control group will be inserted in order to compare the data and further verify the efficiency of the treatment.
Blood samples for bone resorption assay will be collected on the first day of training with the trampoline and 20 weeks.
Each training session will be monitored by detecting heart rate (heart rate monitor) and subjective perception of fatigue (Borg scale).
Each subject will be subjected to two venous blood samples taken at the beginning of the observation and at the end.
The samples thus obtained will be transported in certified containers for the safe transport of biological samples, and, subsequently, processed by the experimenters at the laboratories of the Molecular Biology section of the University of Palermo.
Serum and plasma will be obtained from each blood sample.
All information thus obtained will be recorded in a database in which each person will be identified with a numerical code, in order to comply with current privacy regulations.
Body weight, Barefoot standing height, Body mass index, Body composition will be measured in the different groups of study.
Blood samples will be collected from the different groups of study.
Samples will be analyzed and compared for Osteocalcin, parathyroid hormone, CTX, Calcitonin, Vitamin D Calcium, albumin, Phosphate, Potassium.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Palermo, Italy, 90144
- Sport and Exercise Research Unit, Palermo University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Caucasian
- age: 18-55 years
- currently injury free
- Body mass index between 18.5 and 28 kg/m2
Exclusion Criteria:
- bone fracture within the previous year
- use of medication or suffering from any condition known to affect bone metabolism
- pregnancy
- breastfeeding
- current smokers
- participation in moderate and high impact-activity for ≥3 h·week before enrolling the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: non-exercise group (control group)
The control group not performed physical activity for a total of 20-weeks.
|
|
|
Experimental: exercise group
The exercise group performed SuperJump® training that will be performed for three times a week, each session lasting 60 minutes for a total of 20-weeks.
|
training with trampoline.
Each session lasted sixty minutes.
Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum bone remodelling markers
Time Frame: 20 WEEKS
|
bone resorption CTX and bone formation osteocalcin will be assessed at baseline and after 20weeks
|
20 WEEKS
|
|
Serum bone matabolism markers
Time Frame: 20 WEEKS
|
PTH, calcitonin, Vitamin D, Calcium, Phosphate, Potassium will be assessed at baseline and after 20weeks
|
20 WEEKS
|
|
Plasma concentrations of Gastrointestinal peptides
Time Frame: 20 WEEKS
|
GLP-1, GLP-2, GIP, PYY, Ghrelin will be assessed at baseline and after 20weeks
|
20 WEEKS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
body mass index (BMI)
Time Frame: 20 WEEKS
|
Weight (Kg) Hight (m) BMI (kg/m2) All these measurements will be assessed at baseline and after 20weeks |
20 WEEKS
|
|
body composition
Time Frame: 20 WEEKS
|
lean mass as percent of body weight and fat mass as percent of body weight will be assessed at baseline and after 20weeks
|
20 WEEKS
|
|
insulin
Time Frame: 20 WEEKS
|
measured in plasma will be assessed at baseline and after 20 weeks
|
20 WEEKS
|
|
glucose
Time Frame: 20 WEEKS
|
measured in plasma will be assessed at baseline and after 20 weeks
|
20 WEEKS
|
|
triglicerises
Time Frame: 20 WEEKS
|
measured in plasma will be assessed at baseline and after 20 weeks
|
20 WEEKS
|
|
HDL
Time Frame: 20 WEEKS
|
measured in plasma will be assessed at baseline and after 20 weeks
|
20 WEEKS
|
|
Cholesterol
Time Frame: 20 WEEKS
|
measured in plasma will be assessed at baseline and after 20 weeks
|
20 WEEKS
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Patrizia Proia, PhD, Faculty of Sport and Physical Education, University of Palermo
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2019
Primary Completion (Actual)
January 31, 2020
Study Completion (Actual)
March 3, 2020
Study Registration Dates
First Submitted
June 8, 2021
First Submitted That Met QC Criteria
June 25, 2021
First Posted (Actual)
June 28, 2021
Study Record Updates
Last Update Posted (Actual)
June 28, 2021
Last Update Submitted That Met QC Criteria
June 25, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRAMP2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Perimenopausal Bone Loss
-
University of California, San FranciscoCompleted
-
Penn State UniversityUniversity of Georgia; United States Department of Agriculture (USDA); California...Recruiting
-
University Hospital of North NorwayUniversity of Tromso; Haukeland University Hospital; The International Osteoporosis...CompletedPerimenopausal Bone LossNorway
-
Chonbuk National University HospitalCompletedBone Health in Perimenopausal WomenKorea, Republic of
-
Tongji HospitalRecruitingPerimenopausal SyndromeChina
-
Liaquat University of Medical & Health SciencesUniversity of East Anglia; Activ'insideCompletedPerimenopausal DisorderPakistan
-
Menekşe Nazlı AKERCompleted
-
UnivatesAline Patrícia Brietzke; Ana Paula CostellaCompletedPerimenopausal DisorderBrazil
-
Sohag UniversityRecruitingPerimenopausal BleedingEgypt
-
Columbia UniversityActive, not recruiting
Clinical Trials on physical activity
-
Health Education Research Foundation (HERF)CompletedQuality of LifePakistan
-
Zohra Institute of Health SciencesCompletedPhysical Activity and StressPakistan
-
University GhentCompleted
-
Centre Hospitalier Universitaire DijonWithdrawn
-
Fundacion para la Investigacion y Formacion en...CompletedImpaired CognitionSpain
-
Universidad Santo TomasEmory University; Universidad Pública de Navarra; Universidad de Granada; University... and other collaboratorsCompletedObesity | Lipid Metabolism Disorders | Mental Health Wellness 1 | Body Composition, Beneficial | Metabolic Syndrome X
-
AUSL Romagna RiminiFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruitingNon-Small Cell Lung CancerItaly
-
Centre Hospitalier Departemental VendeeTerminated
-
Fundación para la Investigación del Hospital Clínico...CompletedObesity | Severe Mental Disorder
-
Augusta UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Kansas... and other collaboratorsCompletedMental Disorders, SevereUnited States